Role of oncology clinical pharmacist: a case of life-saving interventions
Keywords:
Clinical pharmacy, Methotrexate, Oncology, Chemotherapy, Pharmaceutical careAbstract
The oncology clinical pharmacist (CP) has a crucial role in cancer patient care through improving medication use including chemotherapy and other high alert medications. As part of multidisciplinary team CP has major role in assuring safe, effective and cost-effective drug therapy. Herein we report a case of 45 years old male patient diagnosed with diffuse large B-cell lymphoma (DLBCL), treated with high dose methotrexate (MTX) as prophylaxis for central nervous system (CNS) lymphoma, and followed up by CP regarding medications related issues. Role of CP is mainly to identify, prevent and manage any drug related problem including drug choice, dosage, interactions, administration and side effects. Oncology CP was very effective in optimizing medication use and has a promising role through providing clinically important interventions regarding medication use. We present this educational case report to show the vital role of CP in patient care by providing important interventions that are effective and sometimes life-saving.
References
Peter J. Kaboli, Angela B, et al. Clinical Pharmacists and Inpatient Medical Care: A Systematic Review. Arch Intern Med 2006;166:955-64.
Jolynn K. Sessions, John Valgus, et al. Oncology Clinical Pharmacists in Light of the Oncology Workforce Study. J Oncol Pract 2010 September; 6(5):270-2.
Chan A, Shih V, Chew L. Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre. J Oncol Pharm Pract 2008 Mar;14(1):23-9.
Ryan N, Chambers C, Ralph C, England D, Cusano F. Evaluation of clinical pharmacists' follow-up service in an oncology pain clinic. J Oncol Pharm Pract 2013;19:151-8.
Altavela JL, Jones MK, Ritter M. A prospective trial of a clinical pharmacy intervention in a primary care practice in a capitated payment system. J Manag Care Pharm 2008 Nov-Dec;14(9):831-43.
Jeremy S. Abramson, Matthew Hellmann, Jeffrey A. Barnes, et al. Intravenous Methotrexate as Central Nervous System (CNS) Prophylaxis Is Associated With a Low Risk of CNS Recurrence in High-Risk Patients With Diffuse Large B-Cell Lymphoma. Cancer 2010;116:4283-90.
Bernstein JI, Coleman CN, et al. Combined modality therapy for adults with small non cleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol 1986 Jun;4(6):847-58.
Cheung CW, Burton C, Smith P, et al. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 2005 Oct;131(2):193-200.
Al-Quteimat OM, Al-Badaineh MA. Methotrexate and trimethoprim–sulphamethoxazole: extremely serious and life-threatening combination. Journal of Clinical Pharmacy and Therapeutics. 2013, doi: 10.1111/jcpt.12060.
Emna Gaies, Nadia Jebabli, Sameh Trabelsi, et al. Methotrexate Side Effects: Review Article. J Drug Metab Toxicol 2012;3:125.
R. Santucci, D. Leveque, A. Lesocoute, et al. Delayed Elimination of Methotrexate Associated with Co-Administration of Proton Pump Inhibitors. Anticancer Research 2010;30:3807-10.
Johnson AG, Seidemann P, Day RO. NSAID-related adverse drug interactions with clinical relevance. An update. Int J Clin Pharmacol Ther 1994 Oct;32(10):509-32.
Ali McBride, Peter Westervelt. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies. Journal of Hematology & Oncology 2012;5:75.
Brigitte C. Widemann, Peter C. Adamson. Understanding and Managing Methotrexate Nephrotoxicity. The Oncologist 2006;11:694-703.
